NICE is unable to make a recommendation about the use in the NHS of enfortumab vedotin for treating locally advanced or metastatic urothelial cancer after platinum-containing chemotherapy and a PD‑1 or PD‑L1 inhibitor. This is because Astellas did not provide an evidence submission. Astellas has confirmed that there is unlikely to be enough evidence that the technology is a cost-effective use of NHS resources in this population.


If NHS organisations wish to consider enfortumab vedotin for this indication, they should follow the advice on rational local decision making in the NHS Constitution for England and the NHS Commissioning Board and Clinical Commissioning Groups (Responsibilities and Standing Rules) Regulations 2012. This outlines the approach that should be taken when there is no NICE guidance.

NICE will review the position if the company decides that it wants to make an evidence submission.

ISBN: 978-1-4731-4637-2

  • National Institute for Health and Care Excellence (NICE)